标题:Persistence and gender differences in protection against severe fever with thrombocytopaenia syndrome virus with natural infection: a 4-year follow-up and mathematical prediction study
作者:Qi, R.; Huang, Y. T.; Yu, X. J.
作者机构:[Qi, R.; Yu, X. J.] Wuhan Univ, Sch Hlth Sci, Wuhan, Hubei, Peoples R China.; [Qi, R.; Yu, X. J.] Wuhan Univ, State Key Lab Virol, Wuhan, Hubei, Peo 更多
通讯作者:Yu, XJ;Yu, XJ
通讯作者地址:[Yu, XJ]Wuhan Univ, Sch Hlth Sci, Wuhan, Hubei, Peoples R China;[Yu, XJ]Wuhan Univ, State Key Lab Virol, Wuhan, Hubei, Peoples R China.
来源:EPIDEMIOLOGY AND INFECTION
出版年:2019
卷:147
DOI:10.1017/S1469440918003643
关键词:Bunyaviruses; emerging infections; epidemiology; SFTS virus
摘要:Severe fever with thrombocytopaenia syndrome (SFTS) is an emerging infectious disease discovered in 2010 and has a case fatality as high as 30%. We intended to study the immune protection conferred by SFTS with natural infection. We collected and analysed 4-year follow- up data to study the characteristics of neutralising antibodies against SFTS virus (SFTSV). The 50% plaque reduction neutralisation test was used for the detection of neutralising antibodies against SFTSV. Geometric mean titres (GMTs) and proportions of patients with a protective titre were analysed, and the persistence of protection was predicted. The titre of antibodies declined yearly in the 4-year study period. Approximately 3 months after infection, the GMT was 143 (95% confidence interval (CI): 89-231), and 100% of patients had a protective titre. In the fourth year, the GMT declined to 53 (95% CI: 37-76), and 95% of patients had a protective titre. The titre was higher in females than in males. On average, the protection offered by neutralising antibodies against SFTSV could last as long as 9 years. The durations of protection were different for different initial titres. The characteristics of neutralising antibodies can be used as a reference for the vaccination doses and schedules of forthcoming vaccines.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062886372&doi=10.1017%2fS1469440918003643&partnerID=40&md5=7ff125ee6f02c22677e990b896bf3dac
TOP